Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis

Published:2021-07 Issue:7 Volume:16 Page:1099-1117
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Liu Lihui,Bai Hua,Wang Chao,Seery Samuel,Wang Zhijie,Duan Jianchun,Li Sini,Xue Pei,Wang Guoqiang,Sun Yiting,Du Xinyang,Zhang Xue,Ma Zixiao,Wang Jie

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference70 articles.

1. The biology and management of non-small cell lung cancer;Herbst;Nature,2018

2. Non-small-cell lung cancers: a heterogeneous set of diseases;Chen;Nat Rev Cancer,2014

3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer, version 4. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450. Accessed June 8th, 2021.

4. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review;Arbour;JAMA,2019

5. Current and emergent therapy options for advanced squamous cell lung cancer;Socinski;J Thorac Oncol,2018

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithetical impacts of deleterious LRP1B mutations in non-squamous and squamous NSCLCs on predicting benefits from immune checkpoint inhibitor alone or with chemotherapy over chemotherapy alone: retrospective analyses of the POPLAR/OAK and CHOICE-01 trials;Science China Life Sciences;2024-09-12

2. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials;Clinical and Translational Oncology;2024-09-12

3. The efficacy and safety of neoadjuvant immunochemotherapy in resectable stage I-III non-small cell lung cancer: a systematic review and network meta-analysis;Clinical and Translational Oncology;2024-09-09

4. The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classification;Cancer Medicine;2024-09

5. Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade;ImmunoTargets and Therapy;2024-09